

POSTER PRESENTATION

Open Access

Preclinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma

Esther Drent^{1*}, Richard Groen¹, Willy Noort¹, Jeroen Lammerts van Bueren², Paul Parren^{2,3,4}, Jürgen Kuball⁵, Zsolt Sebestyen⁵, Niels van de Donk¹, Anton Martens¹, Henk Lokhorst², Tuna Mutis¹

From 30th Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2015) National Harbor, MD, USA. 4-8 November 2015

Background

Adoptive transfer of T cells transduced with tumor-reactive Chimeric Antigen Receptors (CARs) is a promising strategy for cancer immunotherapy. The CD38 molecule, with its high and homogenous expression on Multiple Myeloma (MM) cells, appears a suitable target for antibody therapy. Prompted by this, we evaluated the feasibility of targeting MM with CD38-CAR-transduced (CD38-CAR) T cells.

Methods

We generated three retroviral CAR constructs based on huCD38 antibodies, CD3 ζ and 4-1BB signaling domains and transduced them into T cells of healthy donors and MM patients to test the *in vitro* and *in vivo* efficacy.

Results

Irrespective of the donor, CD38-CAR T cells lost CD38 expression, expanded readily and lysed MM and other malignant cell lines in a cell dose-, and CD38-dependent manner. They also lysed primary malignant cells from acute myeloid leukemia, and multi-drug resistant MM patients. Also in a xenotransplant model, i.v. injected CD38-CAR T cells were effective against MM tumors growing in a human bone marrow-like microenvironment, thus demonstrating their ability to properly migrate and infiltrate into the tumor niche to lyse malignant cells. Although CD38-CAR T cells lysed CD38⁺ monocytes, NK cells, CD34⁺ cells and to a lesser extent CD38⁺ T and B cells, they did not hamper the outgrowth progenitor cells into various myeloid lineages.

Furthermore, CD38-CART cells were controllable with a caspase-9-based suicide gene.

Conclusions

These results signify the potential importance of CD38-CAR T cells as therapeutic tools for CD38⁺ malignancies, including MM, and warrant further safety and efficacy evaluation in appropriate models.

Authors' details

¹VU University Medical Center Amsterdam, Amsterdam, the Netherlands. ²Genmab BV, Utrecht, Utrecht, the Netherlands. ³University of Southern Denmark, Odense, Denmark. ⁴Leiden University Medical Center, Leiden, Utrecht, the Netherlands. ⁵University Medical Center Utrecht, Utrecht, the Netherlands.

Published: 4 November 2015

doi:10.1186/2051-1426-3-S2-P13

Cite this article as: Drent et al.: Preclinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma. *Journal for ImmunoTherapy of Cancer* 2015 **3**(Suppl 2):P13.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit



¹VU University Medical Center Amsterdam, Amsterdam, the Netherlands
Full list of author information is available at the end of the article